Article · Wikipedia archive · Last revised Jul 17, 2026

Phenescaline

Phenescaline, also known as 3,5-dimethoxy-4-phenylethoxyphenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to mescaline. It is the derivative of mescaline in which the methoxy group at the 4 position has been replaced with a phenylethoxy group. In his book PiHKAL, Alexander Shulgin lists phenescaline's dose as greater than 150 mg orally and its duration as unknown. The effects of phenescaline have been reported to include threshold effects and a vague unreal feeling as if one had not had enough sleep. The drug shows affinity for the serotonin 5-HT2A receptor. The chemical synthesis of phenescaline has been described. Phenescaline was first described in the literature by Shulgin in PiHKAL in 1991.

Last revised
Jul 17, 2026
Read time
≈ 1 min
Length
254 w
Citations
9
Source
Wikipedia ↗
Phenescaline
Clinical data
Other names3,5-Dimethoxy-4-phenylethoxyphenethylamine; 4-Phenylethoxy-3,5-dimethoxyphenethylamine
Routes of
administration		Oral1
Drug classSerotonin receptor modulator; Psychoactive drug
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown1
Identifiers
  • 2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H32NO3
Molar mass310.458 g·mol−1
3D model (JSmol)
  • COc2cc(cc(OC)c2OCCc1ccccc1)CCN
  • InChI=1S/C18H23NO3/c1-20-16-12-15(8-10-19)13-17(21-2)18(16)22-11-9-14-6-4-3-5-7-14/h3-7,12-13H,8-11,19H2,1-2H3 checkY
  • Key:FKXBCTFKCKEDNI-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Phenescaline, also known as 3,5-dimethoxy-4-phenylethoxyphenethylamine, is a psychoactive drug of the phenethylamine and scaline families related to mescaline.1 It is the derivative of mescaline in which the methoxy group at the 4 position has been replaced with a phenylethoxy group.1 In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists phenescaline's dose as greater than 150 mg orally and its duration as unknown.1 The effects of phenescaline have been reported to include threshold effects and a vague unreal feeling as if one had not had enough sleep.1 The drug shows affinity for the serotonin 5-HT2A receptor (Ki = 59 nM).2 The chemical synthesis of phenescaline has been described.1 Phenescaline was first described in the literature by Shulgin in PiHKAL in 1991.1

See also

See also

References

References

  1. Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://www.erowid.org/library/books_online/pihkal/pihkal141.shtml
  2. Parker MA, Kurrasch DM, Nichols DE (April 2008). "The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands". Bioorganic & Medicinal Chemistry. 16 (8): 4661–4669. doi:10.1016/j.bmc.2008.02.033. PMC 2442558. PMID 18296055. Compound 21, code PE
External links